Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 4, 2022
SAN DIEGO, July 19, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science...
Vaccine
Bavarian Nordic Secures Significant European Smallpox/Monkeypox Vaccine Order for 2023
Bavarian Nordic to supply an additional 1.5 million doses of IMVANEX® vaccine to an undisclosed European countryDeliveries starting in the...
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a...
U.S. Government Orders Another 2.5 Million Doses of Monkeypox Vaccines from Bavarian Nordic
Bavarian Nordic to supply an additional 2.5 million doses of JYNNEOS® vaccine, bringing deliveries in 2022 and 2023 to a...
Massachusetts tops Sharecare Community Well-Being Index ranking of US states for second consecutive year
As COVID-19 pandemic entered a new phase and changing workforce dynamics reshaped labor market, well-being improved in key well-being and...
Horizon Technology Finance Provides Second Quarter 2022 Portfolio Update
- Horizon Platform Originates Record $192 Million of New Loans in Q2, Including $137 Million of New Loans for HRZN...
Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022
SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker,...
PDS Biotechnology Announces Presentation of Universal Flu Vaccine Preclinical Data at the 41st American Society of Virology Meeting
PDS0202 neutralized multiple strains of influenza and provided protection against infection in preclinical studiesFLORHAM PARK, N.J., July 14, 2022 (GLOBE...
TFF Pharmaceuticals Expands R&D Operations with New Austin Facility
New Facility in Austin Will Enable Increased Capacity for Internal Pipeline Assets While Accommodating Growing Interest in Partnered Projects Significantly...
Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis
Dupixent®(dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis First and...
CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
• Phase 1 dose-escalation study started at clinical sites in the U.S. • Milestone demonstrates CureVac’s and GSK’s continued execution...
CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer
∙ The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics ∙ CureVac RNA Printer...
CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic
Rolling submission to accelerate time to marketing authorization of CVnCoV in SwitzerlandReview process started with submission of first CVnCoV data...
Humanity Supersedes Technology with Covid Vaccines
Lessons from the most important tech adoption of our century: the COVID-19 vaccine By Cameron Turner, VP Data Science and...
CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection
Data provided further evidence on immunogenicity and protective efficacy of CVnCoV ∙ Induction of robust antibody and T cell responses...